Sep 10, 2026 04:05PM
Aug 12, 2026 04:05PM
Jul 28, 2026 06:21AM
Jul 28, 2026 06:15AM
Jul 13, 2026 04:05PM
Jul 13, 2026 04:05PM
Jul 10, 2026 11:49AM AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
Jun 29, 2026 01:59AM
Jun 29, 2026 01:59AM
Jun 17, 2026 12:04PM
Jun 10, 2026 04:05PM
Jun 10, 2026 04:05PM
Jun 9, 2026 12:47PM
Jun 2, 2026 12:05PM AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share
May 25, 2026 12:06PM
May 13, 2026 01:36PM
May 11, 2026 04:05PM
Apr 28, 2026 06:16AM
Apr 28, 2026 06:15AM
Apr 27, 2026 12:06PM
Apr 20, 2026 03:37PM AB Science publishes study showing masitinib survival benefits in ALS patients
Apr 20, 2026 03:32PM
Apr 16, 2026 01:20PM
Apr 13, 2026 04:05PM
Mar 11, 2026 04:05PM
Feb 24, 2026 12:02PM
Feb 11, 2026 04:05PM
Feb 5, 2026 06:22AM AllianceBernstein (AB) Tops Q4 EPS by 4c
Feb 5, 2026 06:20AM
Jan 29, 2026 12:01PM
Jan 29, 2026 12:00PM
Jan 21, 2026 12:02PM
Jan 12, 2026 04:05PM
Jan 7, 2026 12:03PM
Jan 7, 2026 12:02PM AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
Dec 22, 2025 11:57AM
Dec 18, 2025 01:17PM
Dec 15, 2025 12:39PM
Dec 11, 2025 12:29PM
Dec 10, 2025 04:07PM
Dec 10, 2025 04:05PM
Nov 11, 2025 04:05PM AllianceBernstein reports assets under management rise to $869 billion
Nov 11, 2025 04:05PM
Oct 23, 2025 06:21AM
Oct 23, 2025 06:20AM
Oct 16, 2025 02:58PM
Oct 16, 2025 02:57PM
Oct 14, 2025 02:36AM
Oct 14, 2025 02:36AM AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
Oct 10, 2025 12:10PM

1,228,811 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All